PGC-1α overexpression, or ERRα activation, confers growth advantages of breast cancer cells even under limited nutrients, supporting the correlative clinical data that high expression of PGC-1α is associated with poor prognosis, possibly related to the activation of its downstream glutamine pathway target genes [38]. Here, ESRRA is linked to breast cancer.